Non-hodgkin Lymphoma,B Cell Clinical Trials

11 recruiting

Non-hodgkin Lymphoma,B Cell Trials at a Glance

11 actively recruiting trials for non-hodgkin lymphoma,b cell are listed on ClinicalTrialsFinder across 6 cities in 5 countries. The largest study group is Early Phase 1 with 3 trials, with the heaviest enrollment activity in Hangzhou, Beijing, and Ancona. Lead sponsors running non-hodgkin lymphoma,b cell studies include Zhejiang University, Bioray Laboratories, and Chinese PLA General Hospital.

Browse non-hodgkin lymphoma,b cell trials by phase

Treatments under study

About Non-hodgkin Lymphoma,B Cell Clinical Trials

Looking for clinical trials for Non-hodgkin Lymphoma,B Cell? There are currently 11 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Non-hodgkin Lymphoma,B Cell trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Non-hodgkin Lymphoma,B Cell clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 111 of 11 trials

Recruiting
Phase 2

CAR T-cell Therapy in Patients With Renal Dysfunction

Multiple MyelomaAcute Lymphoblastic Leukemia, AdultNon-hodgkin Lymphoma,B Cell
Northside Hospital, Inc.20 enrolled1 locationNCT05909059
Recruiting

SARcopenia and Simplified Geriatric Assessment in Lymphoma Patients Undergoing CAR-T Cell Therapy: the FIL_SAR-CAR Project

Non-hodgkin Lymphoma,B Cell
Fondazione Italiana Linfomi - ETS130 enrolled21 locationsNCT06156774
Recruiting
Phase 1

The Safety and Efficacy of BRL-201 in the Treatment of r/r B Lymphocyte Non-Hodgkin Lymphoma

Non-hodgkin Lymphoma,B Cell
Bioray Laboratories18 enrolled3 locationsNCT05741359
Recruiting
Not Applicable

Universal CAR-T Cell Therapy for NHL

Non-hodgkin Lymphoma,B Cell
Bioray Laboratories6 enrolled1 locationNCT07248163
Recruiting
Not Applicable

LIBERTY: Liquid Biopsy to Diagnose and Monitor CNS Involvement in High-risk B Cell Non-Hodgkin Lymphoma

Non-hodgkin Lymphoma,B Cell
Swiss Cancer Institute64 enrolled14 locationsNCT06090162
Recruiting
Phase 1Phase 2

Novel Allogenic CD19-targeting CAR-γδT Cell Therapy (QH103E) in r/r NHL

Non-hodgkin Lymphoma,B Cell
Chinese PLA General Hospital30 enrolled1 locationNCT06838832
Recruiting
Early Phase 1

Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of r/r B-NHL Clinical Research

Non-hodgkin Lymphoma,B Cell
Zhejiang University36 enrolled1 locationNCT06716164
Recruiting
Early Phase 1

CD19-BAFF CAR-T Cells Therapy for Patients With Relapsed / Refractory B-cell ALL and B-cell NHL

Acute Lymphoblastic Leukemia,B-CellNon-hodgkin Lymphoma,B Cell
Zhejiang University20 enrolled1 locationNCT06346912
Recruiting
Phase 1Phase 2

Allogeneic TRAC Locus-inserted CD19-targeting STAR T Cell Therapy in r/r B-NHL

Non-hodgkin Lymphoma,B Cell
Chinese PLA General Hospital30 enrolled2 locationsNCT06321289
Recruiting
Phase 4

B-cell Mature Non-Hodgkin's Lymphoma Treatment Protocol in Children and Adolescents 2021

Primary CNS LymphomaBurkitt LymphomaNon-hodgkin Lymphoma,B Cell+1 more
Federal Research Institute of Pediatric Hematology, Oncology and Immunology300 enrolled1 locationNCT05518383
Recruiting
Early Phase 1

A Study of Humanized CD19 CAR-T Cells Therapy for Patients With Relapsed and/or Refractory B-cell ALL and B-cell NHL

Acute Lymphoblastic LeukemiaNon-hodgkin Lymphoma,B Cell
Zhejiang University72 enrolled1 locationNCT04532268